Teva(TEVJF)

Israel - Petach TikvaPharmaceutical11 H-1B visas (FY2023)

Focus: Teva is a global pharmaceutical company headquartered in Israel with a portfolio spanning small molecules and biologics across neurology, cardiovascular, oncology, and immunology. A large-cap public company with ~$14.9B in annual revenue (FY2024), Teva operates as both an innovator and generic manufacturer.

Neurology Cardiovascular Oncology Infectious Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 2mo ago

Funding Stage

PUBLIC

Open Jobs

Recent layoff filing — 205 affected

11/18/2025 — Salt Lake City, UT · 205 affected · Layoff Amendment

Source: state DOL filings via Big Local News

About Teva

AI assessmentNot Hiring

No open roles listed right now. Follow Teva to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

5/9 — Partial

Company HealthSolid

Pipeline

Early-stage

50 total

LOE Risk

6 imminent

ADASUVE

Hiring

Stable

Revenue

$1.5B

FY2025

Key Products

AUSTEDO

Huntington disease, tardive dyskinesia, dystonia

$1.1B Part D

Peak12.2yr

Help build intelligence for Teva

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

AUSTEDO franchise (deutetrabenazine) generates $1.1B in Part D spending and anchors a strong neurology portfolio with peak-stage lifecycle products
High R&D intensity (64% of revenue) signals commitment to innovation; 50+ active pipeline programs across Phase 1–4 with near-term Phase 3 catalysts in migraine, schizophrenia, and asthma
Stable cash position ($3.2B FY2025) and diverse therapeutic areas (neurology, cardiovascular, immunology, oncology) offer cross-functional career mobility

Watch Out For

Significant patent cliff exposure: COPAXONE (glatiramer acetate, $369M Part D) faces LOE approaching; LYRICA (pregabalin, $72M) also near cliff—restructuring risk likely
Recent financial deterioration: FY2024 net loss of $2.4B and FY2025 loss of $559M despite $14.9B revenue signals operational or one-time charges; active drug shortages (Adderall, methylphenidate) raise manufacturing/supply chain concerns

Generated by Claude from Teva's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Flagship franchise representing 32% of total revenue; extended-release formulation (AUSTEDO XR, $91M) extends lifecycle to 2041.

COPAXONE

Relapsing-remitting multiple sclerosis, optic neuritis

$369M Part D

LOE Approaching

Second-largest product by revenue but facing generic/biosimilar pressure; transition imminent, creating near-term revenue headwind.

BELBUCA

Opioid use disorder, chronic pain

$150M Part D

Peak6.4yr

Solid specialty pain asset with extended LOE; benefits from opioid-use-disorder market tailwinds.

LYRICA

Fibromyalgia, diabetic neuropathy, postherpetic neuralgia

$72M Part D

LOE Approaching

Generic erosion underway; represents significant patent cliff risk in near to medium term.

Pipeline & Clinical Trials

Digihaler Albuterol Device by TEVA

Asthma in Children

N/A

The Ribavirin Pregnancy Registry

Birth Defects

N/A

Protocol Intervention Group

Huntington Disease

N/A

Clinical Trials (1)

NCT03417583Assessing Efficacy of Neuropsychiatric Assessment and Treatment Protocols in Huntington's Disease Patients

N/A

extra fine particle hydrofluoroalkane beclomethasone dipropionate via metered dose inhaler

Asthma

N/A

Clinical Trials (1)

NCT01400217Qvar Versus Clenil, a General Practice Research Database Study

N/A

Systematic detection of vascular risk factors and subsequent evidence-based treatment

Stroke

N/A

ProAir Digihaler

COPD

N/A

Clinical Trials (1)

NCT04821869ProAir Digihaler in COPD Disease Management: A Real World Study

N/A

Copaxone

Multiple Sclerosis

N/A

Clinical Trials (4)

NCT00203073A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis.

Phase 2

NCT00202982A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose

Prospective Observational Study in Patients With Metastatic Breast Cancer Treated With Anthracycline

Metastatic Breast Cancer

N/A

Clinical Trials (1)

NCT01555944Prospective Observational Study in Patients With Metastatic Breast Cancer Treated With Anthracyclines

N/A

formoterol

Asthma

N/A

Clinical Trials (2)

NCT05831566Expertise Asthma COPD Program with Digital Support

Phase 3

NCT00643578Dose-response of Inhaled Formoterol Using Methacholine Challenge as a Bioassay

N/A

rasagiline mesylate

Parkinson's Disease

N/A

Naturalistic Adasuve Clinical Trial Study

Agitation

N/A

Clinical Trials (1)

NCT02877108Naturalistic Adasuve Clinical Trial Study

N/A

Initiation of beclometasone via the Easibreathe device plus salbutamol via the Easibreathe device

Asthma

N/A

Clinical Trials (1)

NCT01313585Device Mixing in Asthma, a General Practice Research Database Study

N/A

Extra-fine hydrofluoroalkane-beclomethasone dipropionate

Asthma

N/A

Clinical Trials (1)

NCT01141439Real-world Effectiveness and Cost-effectiveness of Leading Inhaled Corticosteroids in Asthma Management

N/A

Smoking

Asthma

N/A

Clinical Trials (1)

NCT02833727Airway Inflammation and Disease Burden in Asthmatic Smokers

N/A

Sleep Recording

Parkinson Disease

N/A

Clinical Trials (1)

NCT02907723Feasibility of Continuous Sleep Recording in Patients Undergoing Deep Brain Stimulation for Parkinson's Disease

N/A

NAbs testing

Multiple Sclerosis

N/A

Clinical Trials (1)

NCT00336557Determine Impact of Multiple NAb Tests on Treatment Compared to Usual Care of MS Patients on High-dose IFN Therapy

N/A

Group R+AD Rasagiline + Antidepressant

Serotonin Syndrome

N/A

Clinical Trials (1)

NCT00955604Azilect + Antidepressant Chart Review

N/A

tDCS

Relapsing Remitting Multiple Sclerosis

N/A

Clinical Trials (1)

NCT02266121Improving Cognitive Aptitudes With tDCS in Patients With Multiple Sclerosis

N/A

Albuterol eMDPI DS

Pulmonary Disease, Chronic Obstructive

N/A

Clinical Trials (1)

NCT05241288Digihaler in Chronic Obstructive Pulmonary Disease (COPD)

N/A

The Mycophenolate Pregnancy Registry

Heart Transplantation, Kidney Transplantation, Liver Transplantation, Autoimmune Diseases

N/A

Correlation Between PET and Advanced MRI in Multiple Sclerosis

Multiple Sclerosis

N/A

Clinical Trials (1)

NCT02869360Correlation Between PET and Advanced MRI in Multiple Sclerosis

N/A

Qvar Therapy in Smoking Asthmatics

Asthma

N/A

Clinical Trials (1)

NCT01729351Qvar Therapy in Smoking Asthmatics

N/A

A Survey Study to See if Patients Diagnosed With Parkinson's Disease Have Higher Incidence of Melano

Parkinson's Disease

N/A

Clinical Trials (1)

NCT00203008A Survey Study to See if Patients Diagnosed With Parkinson's Disease Have Higher Incidence of Melanoma

N/A

Marketed antagonists

Asthma

N/A

Clinical Trials (1)

NCT02419872Study in Patients' With Persistent Asthma and Chronic Obstructive Pulmonary Disease

N/A

Rasagiline mesylate

Parkinson's Disease

N/A

Clinical Trials (1)

NCT01032486Study for Rasagiline Effect on Sleep Trial(REST)in Parkinson's Disease

N/A

Azilect

Parkinson's Disease

N/A

Clinical Trials (2)

NCT02207387Ambulosono Rasagiline Musical Walking Study

N/A

NCT02384512Azilect® In Wearing-Off (AIWO)

N/A

level of agitation

Psychiatric Issue

N/A

Clinical Trials (1)

NCT02713100Self Reported Level of Agitation of Patients Presenting to an Emergency Department

N/A

Fremanezumab

Migraine

N/A

Clinical Trials (1)

NCT03539393Fremanezumab Compassionate Use Program for Pediatric Patients

N/A

Glatiramer acetate

Multiple Sclerosis

N/A

Clinical Trials (1)

NCT00819195Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis

N/A

Training on BF Spiromax followed by SYMBICORT Turbohaler

Asthma

N/A

Clinical Trials (1)

NCT02570425Comparing Maintenance of Device Mastery With Turbohaler© vs. Spiromax© in Healthcare Professionals naïve to Both Devices

N/A

Effentora®

Cancer

N/A

Clinical Trials (1)

NCT01400854Effentora® in Clinical Practice - a Non-interventional Study to Evaluate Satisfaction and Tolerability

N/A

Bach's Rescue Remedy Cream

Multiple Sclerosis

N/A

Clinical Trials (1)

NCT00972062Herbal Therapy for Subcutaneous Injection Site Reactions in Multiple Sclerosis

N/A

Modafinil/armodafinil

Narcolepsy

N/A

Clinical Trials (1)

NCT01792583The Nuvigil and Provigil Pregnancy Registry

N/A

Extra-fine hydrofluoroalkane-beclometasone dipropionate

Asthma

N/A

Clinical Trials (1)

NCT01697722Real-world Effectiveness and Cost-effectiveness of HFA-beclometasone Compared With ICS/LABA Combination Therapy

N/A

Adenovirus Vaccine Pregnancy Registry

Adenovirus

N/A

Clinical Trials (1)

NCT01584037Adenovirus Vaccine Pregnancy Registry

N/A

Studying the Effects of Copaxone on Retinal Health Using Optical Tomography Over 24 Months

Multiple Sclerosis

N/A

Clinical Trials (1)

NCT02017808Studying the Effects of Copaxone on Retinal Health Using Optical Tomography Over 24 Months

N/A

Ovaleap®

Pregnancy Rate

N/A

Clinical Trials (1)

NCT02809989A Study to Evaluate the Effect of Ovaleap® on the Pregnancy Rate and Clinical Effects as Well as the User-friendliness of the Ovaleap®-Pen.

N/A

Bradykinesia UPDRS Motor Full Examination

Parkinson's Disease

N/A

Clinical Trials (1)

NCT00932581Bradykinesia Subscale Administered Alone Versus Regular Administration: Psychometric Properties

N/A

Cost-effectiveness Study of miRview™ Mets in Patients With Cancer of Unknown Primary (CUP)

Neoplasms, Unknown Primary

N/A

Clinical Trials (1)

NCT01202786Cost-effectiveness Study of miRview™ Mets in Patients With Cancer of Unknown Primary (CUP)

N/A

Mindfulness based stress reduction

Multiple Sclerosis

N/A

Clinical Trials (1)

NCT01419301Mindfulness Based Stress Reduction in Multiple Sclerosis (MS)

N/A

Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effe

HIV Infections

N/A

Budesonide, Formoterol Fumarate Dihydrate

Patient Satisfaction

N/A

Clinical Trials (1)

NCT02384577Study to Evaluate Satisfaction and Usability of DuoResp® SPIROMAX® in Asthma and COPD Treatment

N/A

Immediate postpartum placement of IUD

Contraception

N/A

Clinical Trials (1)

NCT02024672Monitoring With Ultrasound Imaging of Intrauterine Device (IUD) Position Placed Immediately After Giving Birth

N/A

Glatiramer Acetate, IFN-beta 1a

Multiple Sclerosis

N/A

Clinical Trials (1)

NCT00819000Therapy Optimization in Multiple Sclerosis (MS)

N/A

A Study to Evaluate Readiness to Self-inject on Adherence and Compliance to Copaxone® Therapy

Multiple Sclerosis

N/A

Clinical Trials (1)

NCT00238654A Study to Evaluate Readiness to Self-inject on Adherence and Compliance to Copaxone® Therapy

N/A

Extra-fine hydrofluoroalkane beclometasone dipropionate

Asthma

N/A

Clinical Trials (1)

NCT01877954Qvar vs FP in Pediatrics

N/A

Polysomnogram

Obstructive Sleep Apnea

N/A

Clinical Trials (1)

NCT01340781Screening Tools for Obstructive Sleep Apnea (OSA) in Hospitalized Medical Patients

N/A

Glatiramer acetate

Multiple Sclerosis

N/A

Fremanezumab

Migraine

N/A

BUSPAR® 30 mg Tablet

Healthy

PHASE_1

Clinical Trials (1)

NCT00840398Buspirone Hydrochloride 30mg Tablets, Non-Fasting

Phase 1

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 4092 approved products, 147 clinical trials

Top TAs: Neurology, Cardiovascular, Oncology

H-1B (2023): 11 approvals

SEC Filings: 2 available

Portfolio Health

Pre-Launch737 (18%)

Launch2 (0%)

Growth7 (0%)

Peak53 (1%)

LOE Approaching149 (4%)

Post-LOE3144

Therapeutic Area Focus

Neurology

741 marketed124 pipeline

Cardiovascular

620 marketed1 pipeline

Oncology

244 marketed89 pipeline

Infectious Diseases

263 marketed3 pipeline

Financials (FY2025)

Revenue

$1.5B90%

R&D Spend

$953M(64%)14%

Net Income

-$559M

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Risk Signals

WARN Act Layoff Notices (2)

2025-11-18

205 employees affected— Salt Lake City, UT

2025-06-20

54 employees affected— Salt Lake City, UT

Source: state DOL filings, aggregated via Big Local News

7 active drug shortages

Active shortages (Adderall, methylphenidate, hydroxocobalamin) on Teva products raise supply-chain/manufacturing red flags; no recent WARN filings visible, but operational strain evident.

ORAL · FOR SUSPENSION

NCT00203086A Study to Evaluate the Long Term Safety and Effectiveness of Novantrone Therapy Followed by Copaxone Treatment for Multiple Sclerosis

N/A

164 marketed87 pipeline

Immunology

217 marketed19 pipeline

Metabolic Diseases

182 marketed1 pipeline

Gastroenterology

118 marketed3 pipeline

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Teva(TEVJF)

About Teva

Why Work Here

Key Products

Watch Out For

Products & Portfolio (515)

Key Products by Revenue

Other Products (479)

Pipeline & Clinical Trials

Recent News · Teva(10)

Open Jobs (0)

Financials (FY2025)

Hiring Trend

Visa Sponsorship

Risk Signals

WARN Act Layoff Notices (2)